Important Note: Redirection of Services to ChiCTR
We would like to inform you that the Clinical Trial Registry page will discontinue the function of updating trial information directly on this platform. However, you will still be able to view the existing registration details. For any updates to trial information, you can use the China Clinical Trial Registry (ChiCTR) directly at https://www.chictr.org.cn. This change will be fully implemented by 2024-Aug-05. Thank you for your attention.
CUHK_CCT00119
2007-09-11
Retrospective
N/A
Departmental
Department of Paediatrics, The Chinese University of Hong Kong
N/A
Albert Martin Li
Department of Paediatrics, PWH, Shatin, Hong Kong
Telephone #: 26322859; Fax #: 26360020;
albertm68mcli@yahoo.com
Department of Paediatrics, Faculty of Medicine, The Chinese University of Hong Kong
Albert Martin Li
Department of Paediatrics, Prince of Wales Hospital, Shatin, Hong Kong
Telephone #: 26322859; Fax #: 26360020;
albertm68mcli@yahoo.com
Department of Paediatrics, Faculty of Medicine, The Chinese University of Hong Kong
Nasal Corticosteroids as Treatment for Childhood Obstructive Sleep Apnoea.
Nasal Corticosteroids as Treatment for Childhood Obstructive Sleep Apnoea.
N/A
Hong Kong SAR
Yes
2004-03-02
Childhood Obstructive Sleep Apnoea
Drug
Nasonex
4 months
Placebo. The appearance and smell of the corticosteroids and placebo are indistinguishable.
Inclusion criteria: Once the subjects have completed the overnight PSG, they will be invited to participate in this current study if they satisfied the followings: (1) Confirmed OSAS with a respiratory disturbance index (RDI) of between 1 and 10. It is our current practice to offer children with moderate-severe OSAS (RDI > 10) surgical intervention in the form of adeno-tonsillectomy. (2) Informed consent obtained from parents.
Exclusion criteria: (1) Children with genetic syndromes, congenital or acquired neurological diseases, neuromuscular diseases, and those who have had previous upper airway surgery. (2) Children with fixed nasal obstruction such as previous nasal fracture or deviated nasal septum.
6
18
Both Male and Female
Interventional
Randomized
Placebo
Double-blind
Parallel
2006-05-27
52
Complete
The primary outcome is the change from baseline the various respiratory parameters as documented by overnight polysomnography after a 4-month treatment.
The secondary outcome is the change from baseline the adenoidal size as assessed by standardized lateral neck radiograph after a 4-month treatment.
2011-04-04
Yes
N/A
|
|
|
|
|
---|---|---|---|---|
No documents yet. |